Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
Abstract Recent advances in diagnosis and treatment are enabling a more targeted approach to treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit tumor progression and provide a favorable prognosis in clinical practice. Activating mutations of epidermal growt...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Molecular Cancer |
Online Access: | http://link.springer.com/article/10.1186/s12943-018-0777-1 |